Compare IDEXX Laboratories, Inc. (IDXX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? IDEXX Laboratories, Inc. trades at $573.96 (market cap $46.22B), while NEOS S&P 500 High Income ETF trades at $54.25. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SPYI | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $54.19 |
52-Week Low | $526.44 | $47.98 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
SPYI trades at $54.23, up 0.07% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering a distribution yield near 12%. Recent news highlights its appeal for retirement income but raises concerns about fee gaps and potential over-reliance on volatility for payouts.
The outlook is mixed: SPYI provides tax-efficient yield for income investors but faces risks from declining volatility and capital erosion. Wall Street debates sustainability, with some analysts bullish on its strategy while others warn of hidden costs. Investors should weigh high distributions against long-term principal preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
